Authors
Latest:
High-Stakes Manufacturing: Mitigating the RisksHow to navigate the production and reimbursement intricacies of bringing regenerative medicines from bench to bedside.
Latest:
High-Stakes Manufacturing: Mitigating the RisksHow to navigate the production and reimbursement intricacies of bringing regenerative medicines from bench to bedside.
Latest:
Four Takeaways from the Zolgensma Pricing StormFour takeaway messages from the Zolgensma pricing storm
Latest:
Routes to Exclusivity in Cell-Based Therapy DevelopmentOutlining the critical steps for companies in controlling market exclusivity for their gene therapies.
Latest:
Routes to Exclusivity in Cell-Based Therapy DevelopmentOutlining the critical steps for companies in controlling market exclusivity for their gene therapies.
Latest:
Are Outcomes-Based Deals Only a Band-Aid for High Drug Prices?Outcomes-based contracts seem to have the potential to make drugs more affordable, but not without mutually-beneficial, data-driven arrangements.
Latest:
Pharma Automation: Avoiding the DangersThe key steps to evading automation-fueled data crises.
Latest:
Career Paths and Title Inflation in the Pharmaceutical IndustryDo’s and Dont’s while facing the increased war for talent.
Latest:
Gene Therapy: The Road to IndustrializationClive Glover and Mark Szczypka discuss the complexities of scaling up the manufacturing of gene therapies and gene-modified cell therapies to industrial levels.
Latest:
Building Healthcare Organizations That Put People FirstEvery healthcare company should be striving to identify better ways to ensure patients and consumers inspire every decision they make, writes Joanne Waldstreicher.
Latest:
A Bold Deal Could Help Trump Administration End HIV in AmericaThe US could theoretically treat every single American living with HIV without spending an extra dollar on drugs. And President Trump can broker a deal to do it, write Anil Soni and Ya’ir Aizenman.
Latest:
Liberating Patient DataAiden Flynn discusses mining real-world data pools to transform drug development.
Latest:
Medical Devices' Big Regulatory Shake-Up: What Now?Ben Jacoby assesses the scope for disruption of the significant changes in medical device transparency and traceability requirements, and advises on a practical response.
Latest:
Shifting Patent Litigation Trends Favor Branded Pharma CompaniesThe latest trends in patent litigation has led to a more harmonized patent system, which can benefit pharmaceutical companies that invest in patents.
Latest:
The Synergistic OrganizationA key question for an organization post-M&A is: “What organizational capabilities support global guidance and leadership, and which of them require these at the 'local' level?” Scott Hull discusses potential solutions.
Latest:
A Blueprint for BalanceStephen Rivera, vice president, global technical accounting advisory services and policy, Johnson & Johnson, capitalizes on his lively personality—and a courageous career journey—to bring people together to shape the future of biopharma.
Latest:
Attacks on Pharmaceutical Improvement PatentsIs Congress harming pharmaceutical research by limiting enforcement of improvement patents?
Latest:
Attacks on Pharmaceutical Improvement PatentsIs Congress harming pharmaceutical research by limiting enforcement of improvement patents?
Latest:
Innovation + Human Engagement = Optimal Patient SupportPatient support program providers should incorporate new technologies for more effective processes, but this should be matched with empathy, human connectivity and personalized clinical interventions, writes Tommy Bramley.
Latest:
Creating Reliable Data Foundations for AISteve Gens and Remco Munnik offer five best-practice tips for achieving a definitive, trusted regulatory and product information asset base capable of supporting intelligent innovation.
Latest:
Managing the 3 Fronts of the Drug Pricing Conundrum: Policy, Creativity, CollaborationThe impacts of disruptive curative therapies and advances in the future of health will be profound. To be best positioned for success, healthcare systems under continuous cost pressure must address three key areas, writes Thomas Unger.
Latest:
Emerging Biopharma Tackles the Opioid CrisisDr. Steven Fox, CEO of Akelos Inc., discusses the challenges of developing new non-opioid medical products as the need intensifies as the crisis worsens.
Latest:
Product Development: The Optimizer’s CurseReoccurring disappointment in development portfolios-why it happens and how to mitigate it.
Latest:
Why Pharma’s Approach to IDMP Today Will Matter to Patients & Physicians TomorrowThe Identification of Medicinal Products (IDMP) software industry has talked up the broader potential of data-driven processes. Pharma companies and their software providers have an important role to play in realizing these processes. Frits Stulp discusses the foundations that need to be laid for lasting transformation of pharma information access in the real world.
Latest:
Digital Talent & Real EstateBiopharma companies hungry for digital talent must evaluate their real estate portfolio and workplace strategies to access new talent pools, says Joanne Henderson.
Latest:
Pre-launch Prep: The Modern ProtocolTech-driven changes to training and learning systems-and how brand information is provided and shared-are overhauling approaches to sales rep preparation.
Latest:
Post-Launch Birthday: The Time to RefineFollowing a new product’s first year on the market, there are four key ways companies can refine commercial strategies to maximize product sales.
Latest:
Post-Launch Birthday: The Time to RefineFollowing a new product’s first year on the market, there are four key ways companies can refine commercial strategies to maximize product sales.
